J&J ad­vances through PhII with a promis­ing hep C triple and 100% cure rate

Cur­ing he­pati­tis C is a done deal now. But J&J is step­ping through the clin­ic with a new com­bo that the phar­ma gi­ant hopes will prove it can do it all faster, and pre­sum­ably cheap­er, than what’s avail­able now.

In a new batch of da­ta put out Fri­day morn­ing by J&J part­ner Achillion $ACHN, J&J’s team scored a 100% cure rate in three co­horts of pa­tients get­ting a triple com­bi­na­tion of odalasvir, AL-335 and Oly­sio (simepre­vir). A fourth co­hort that ex­clud­ed simepre­vir achieved a 90% cure rate at SVR12, 12 weeks af­ter treat­ment. And one of the triplet co­horts achieved 100% cure for 20 pa­tients af­ter just 6 weeks of treat­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.